Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
about
Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@en
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@nl
type
label
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@en
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@nl
prefLabel
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@en
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P1476
Lenalidomide and cyclophospham ...... ion-resistant prostate cancer.
@en
P2093
F R Loberiza
H C Britton
J E Talmadge
J K Schwarz
T R McGuire
P2860
P2888
P304
P356
10.1007/S10585-015-9696-3
P577
2015-01-25T00:00:00Z